Limitations of morphology-based management for immune checkpoint inhibitor-related cutaneous adverse events

J Am Acad Dermatol. 2021 Jun;84(6):e281-e282. doi: 10.1016/j.jaad.2021.01.054. Epub 2021 Jan 23.

Authors

Tracey S Otto¹, Michael S Chang², Leah L Thompson², Steven T Chen³

Affiliations

¹ Department of Dermatology, Massachusetts General Hospital, Boston, Massachusetts; Rutgers Robert Wood Johnson Medical School, New Brunswick, New Jersey.
² Department of Dermatology, Massachusetts General Hospital, Boston, Massachusetts; Harvard Medical School, Boston, Massachusetts.
³ Department of Dermatology, Massachusetts General Hospital, Boston, Massachusetts. Electronic address: [email protected].

PMID: 33493573
DOI: 10.1016/j.jaad.2021.01.054

No abstract available

Publication types

Letter
Comment

MeSH terms

Administration, Cutaneous
Humans
Immune Checkpoint Inhibitors*
Skin*

Substances

Immune Checkpoint Inhibitors